*, p= 0. 01, n= 6. and inhibition of platelet activation and collectiong. Our studies show that NO is formed by red blood cells and inhibits platelet activation. Nitric oxide formation and signaling can be recapitulated with isolated deoxyhemoglobin. Importantly, there is limited NO production from erythrocytic xanthine oxidoreductase and nitric-oxide synthase. Under certain conditions we find dorzolamide (an inhibitor of carbonic anhydrase) results in diminished nitrite bioactivation, but the role of carbonic anhydrase is abrogated when physiological concentrations of CO2are present. Importantly, carbon monoxide, which inhibits hemoglobin function as a nitrite reductase, abolishes nitrite bioactivation. Overall our data suggest that deoxyhemoglobin is the primary erythrocytic nitrite reductase operating under physiological conditions Radezolid and accounts for nitrite-mediated NO signaling in blood. == Introduction == At one time nitrite was thought to be biologically inert (1). However , it is now recognized that nitrite plays important roles in various physiological processes, such as blood pressure control, hypoxic vasodilation, and the inhibition of platelet activation, and its use is being explored for various therapeutic applications (24). For example , supervision of nitrite by infusion has been shown to increase blood flow, and its physiological supervision through dietary nitrate has been shown to decrease blood pressure (510). These actions have been associated with production of NO from nitrite reduction in the vasculature (5). Moreover, reduction of nitrite to nitric oxide (NO) has been shown to occur preferentially under hypoxic conditions (5), suggesting a role in hypoxic-NO signaling. Although the ability of nitrite to modulate blood flow is now widely accepted, its mechanism of bioactivation remains controversial. Deoxygenated (HbFe2+) or partially deoxygenated hemoglobin (Hb) was originally hypothesized to be responsible based on the reaction originally proposed by Brooks (11). Here, deoxygenated hemoglobin (deoxyHb) reduces nitrite to NO and forms methemoglobin (metHb). The reaction is potentiated in hypoxia and acidosis (5, 12, 13). A major challenge to the notion that deoxyHb is responsible for nitrite reduction to NO is that once NO is formed in the red blood cell (RBC)5, it will quickly bind to another deoxyHb or react with oxygenated hemoglobin (oxyHb) to form metHb and nitrate. Both of the these reactions are extremely fast (37 107m1s1) (1418), and the formation of nitrate from NO is irreversible in blood. Thus, based on an analysis of these rate constants, NO formed in the red blood cell is not likely to escape scavenging. Several pathways have been proposed that could potentially lead to the export of NO activity from the red cell (1927), but none of these Radezolid proposed mechanisms has been proven, and all have been challenged (28, 29). Other proposed mechanisms to explain the nitrite role in modulating blood flow include reduction to NO in NOS3 the vessel by xanthine oxidoreductase (XOR) (9, 30, 31), aldehyde oxidase (30), or smooth muscle myoglobin (32, 33). However , several lines of evidence support a role for the erythrocyte. Experiments performed with aortic ring bioassays showed that nitrite-mediated vasodilation, which increases as the oxygen tension decreases, is increased when red blood cells are present (5). Although this action of red blood cells was challenged in one study (34), subsequent studies clearly demonstrate that NO scavenging by Hb is counterbalanced by nitrite-mediated NO production from deoxyHb (35, 36). More recently, significant support for a physiological role of the red blood cell in the bioactivation of nitrite and Radezolid NO signaling comes from studies examining platelet activation by nitrite and red cells (35, 37, 38). NO is known to inhibit platelet activation via soluble guanylate cyclase activation and cGMP signaling (3942). Whereas nitrite alone has no effect on platelet activation, when nitrite is added in combination with red blood cells, platelet activation is inhibited in association with intracellular platelet cGMP formation (37). The inhibition of.